Online Order Get In Touch

What are you looking for?

HBV Hepatitis B modeling-rAAV

  • Hepatitis B is a serious and debilitating human disease caused by hepatitis B virus (HBV) infection. HBV infection is species-specific with a narrow host range. Chimpanzees may be considered the most effective host for the study of HBV infection when considering HBV infection rate and maintenance. However, the study of HBV in chimpanzees is heavily limited due to multiple ethical considerations. Tree shrews may serve as an alternative animal model for HBV infection, yet several shortcomings including the low infection rate, infection maintenance time, stability and repeatability limit the utility of Tree Shrews for HBV research. Due to these limitation associated with non-human primate models for the study of HBV mice with a uniform genetic background are often considered the best choice for HBV infection studies.

    PackGene’s AAV-HBV carries a 1.3×HBV full-length genome, and a mouse model of persistent HBV infection can be prepared by one-time tail vein injection of AAV-HBV. This approach has several advantages including simple preparation, high success rate, uniformity, stability, a well-characterized dose-effect relationship, and a wide application range. Furthermore, the HBV-AAV mouse model has been validated and used across a wide range of HBV drug evaluations and vaccine screenings.

    In addition to the advantages listed above, use of the AAV-HBV mouse model can greatly shorten preparation time for in vivo hepatitis B infection therapy research and development. This, when paired with the model’s low cost, can help accelerate the development of hepatitis B drug research and treatment programs. PackGene’s AAV-HBV viral vectors provide long terms stable expression of hepatitis B antigen for the fast and safe modeling of HBV.

    PackGene’s rAAV offers unparalleled safety compared to Lentivirus and Adenovirus, with minimal risk of genome integration, low immunogenicity, and high operational safety. It’s widely used for long-term gene expression, lasting over a decade in some cases, and its diverse serotypes enable organ-specific targeting, such as AAV8’s preference for liver research and its role in creating the AAV-HBV mouse model.

academic promotion

PackGene Referral Program

Refer a friend, get 20% off — and they save 20% too!

Promo Code: New2025
Contact Us

Features of HBV rAAV Vector

  • Highest Security

    Compared with Lentivirus and Adenovirus, rAAV shows outstanding safety advantages including an low probability of genome integration, low immunogenicity, and high experimental operation safety.

  • Long-term Transduction

    Over the past 20 years, rAAV has been commonly used as a tool for efficient and long-term gene expression in basic research and clinical gene therapy. For example, rAAV induced transgene expression in non-human primate muscle tissue can last for more than 10 years.

  • Organ Specificity

    The capsid proteins of different AAV serotypes recognize different receptors on the cell surface, cell infection efficiency varies across tissues, indicating organ targeting specificity. AAV8 is frequently used in liver research and is therefore the serotype of choice for generation of the AAV-HBV mouse model.

Our Advantages

  • Low Empty Shell

    AAV-HBV TEM detects empty shell rate is below 30%

  • Low Endotoxin

    Low endotoxin levels with <10EU/ml – suitable for animal experiments.

  • AAV-HBV Mycoplasma Test Negative

  • High Purity Titer

    ≥1E+13GC/ml for AAV8-based qPCR genome copies/ml

  • Complete Quality Inspection Reports Are Provided

Products Details

Catalog No. Promoter type Genotype and serotype
AAV-D#2012 ssAAV-HBV-D,ayw HBV-D, serotype ayw (The AAV virus harbors the l.3XHBV genome, belonging to genotype D and serotype ayw. This strain is capable of generating HBV DNA, HBeAg, and HBsAg. Originally employed in cell models and transgenic animals, it has become extensively utilized in contemporary HBV research. It is suitable for both cell and animal experiments.)
AAV-C-10433 ssAAV-HBV-C,adr HBV-C, serotype adr (The AAV virus carries the 1.3XHBV genome, belonging to genotype C2 and serotype adr. It can produce HBV DNA, HBeAg, and HBsAg. The C-type HBV is a prevalent strain, known for its strong pathogenicity, although its mechanism remains unclear. It should be given careful consideration in drug development. Suitable for both cell and animal experiments.)
AAV-C-542 ssAAV-HBV-B, adw HBV-B, serotype adw (The AAV virus harbors the 13XHBV genome, characterized by genotype B and serotype adw. It has the ability to produce HBV DNA, HBeAg, and HBsAg. Although the B-type HBV is also common, its pathogenicity is comparatively weaker than that of the C-type. However, it still warrants attention in drug development. Suitable for both cell and animal experiments.)

Notice
50ul and 100ul specification are available.

Technical Details

  • Operation Requirements

    In 1994, the safety of rAAV as a gene therapy vector was recognized by the FDA. AAV are classified as biological safety is Grade 1 (BSL-1), which is the same as that of plasmid DNA. It is nevertheless recommended to adhere to BSL-2 laboratory precautions with a ClassⅡ biological safety cabinet for use.

  • Storage Requirements

  • Designing AAV-HBV Mouse Model

Contact Us

Download